Physician profile
John Tomich
NPI 1962965434
$5,051.94
in general payments reported to CMS, 2019-2025
12 companies · $1,771 in 2025
The $1,771 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.97 · 2021: $122 · 2022: $316 · 2023: $1,232 · 2024: $1,591 · 2025: $1,771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,582 · Education: $10.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,582.37 |
| Education | $10.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,476.87 | 2022-2025 | Biktarvy, Yeztugo, Descovy |
| Viiv Healthcare Company | $1,495.44 | 2023-2025 | Dovato, Rukobia, Cabenuva |
| Merck Sharp & Dohme LLC | $476.47 | 2023-2025 | Pifeltro, Delstrigo, Dificid |
| Janssen Products, LP | $124.23 | 2023 | Symtuza |
| United Therapeutics Corporation | $121.76 | 2021 | |
| Janssen Biotech, INC. | $116.71 | 2022-2023 | Symtuza |
| Theratechnologies INC. | $81.22 | 2023-2025 | Trogarzo, Egrifta |
| Napo Pharmaceuticals INC | $72.60 | 2024 | Mytesi |
| Qiagen, LLC | $35.41 | 2023-2024 | Quantiferon-Tb Gold Plus |
| Abbvie INC. | $26.81 | 2023 | Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $20.97 | 2019 | |
| Janssen Scientific Affairs, LLC | $3.45 | 2023 | Symtuza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tomich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.